CB5138-3 - IPF and Other Fibrotic Diseases
We are developing CB5138-3 for the treatment of IPF. In August 2020, we presented data on the efficacy of CB5138 Analog peptides in preclinical models of IPF at the American Thoracic Society Virtual Annual Meeting. In a widely used therapeutic mouse model of IPF, CB5138-3 significantly reduced lung fibrosis, as evidenced by decreases in the Ashcroft Score, fibrosis-related changes in lung weight, collagen deposition in lung tissue and collagen secretion into lung fluid.
CB5138-3 is currently in IND-enabling studies and we expect to file our IND in the second half of 2023 and commence a First-in-Human study shortly thereafter. While our initial indication is IPF, we are also studying CB5138 Analogs in preclinical models of other fibrotic diseases.View Candidate